Targeting the PI3K/mTOR pathway

Bookmark and Share
Published: 17 May 2012
Views: 3888
Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Dr Lewis Cantley talks to ecancer about PI3K and the development of inhibitors for clinical use at IMPAKT 2012 in Brussels, May 2012.


PI3K, phosphoinosititde 3-kinase is a signalling pathway that controls growth. PI3K is the most frequently mutated gene in breast cancer. Currently, there are 20 inhibitors in phase 1 or 2 trials.


Dr Cantley mentions that there has been good response in phase 1 trials, but while many patients had very good reactions, others did not respond.


The message to take away from this is that doctors should be more aggressive in doing mutational analyses and, more importantly, that this information become more accessible for retroactive analysis for other targetable mutations. 


Filming Supported by Amgen